Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients

Exclusion Criteria

• •Subjects with atypical, secondary or drug-induced Parkinsonism
• •Subjects with a Mini-Mental State Examination (MMSE) score \<25
• •Any known contraindication to the use of levodopa, including a history of malignant melanoma or a history of narrow-angle glaucoma.
• •Subjects who have had a clinically significant illness within 4 weeks of first dose, as determined by the Investigator.
• •Any advanced, severe or unstable disease (other than PD) that may interfere with the primary and secondary study outcome evaluations
• •Subjects who have undergone prior neurosurgical operation for PD or transcranial magnetic stimulation.
• •Subjects who are participating in another clinical study (eg, attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to the baseline visit.
• •Female subjects of childbearing potential
• •Subjects who are pregnant (as determined by positive serum pregnancy test at screening and/or baseline), breastfeeding or lactating.
• •Subjects who, in the opinion of the Investigator, should not participate in this study.